Drugs / HSK46575
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07007910 | Dec 2024 → Dec 2026 expected | prostate carcinoma | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK46575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07007910 ↗ |
| Route | Oral | “co-administered with glucocorticoid and fludrocortisone, orally daily” NCT07007910 ↗ |